NAD + attenuates cardiac injury after myocardial infarction in diabetic mice through regulating alternative splicing of VEGF in macrophages

Lei Jiao,Manyu Gong,Xuewen Yang,Mengmeng Li,Yingchun Shao,Yaqi Wang,Haodong Li,Qi Yu,Lihua Sun,Lina Xuan,Jian Huang,Yanying Wang,Dongping Liu,Yunmeng Qu,Xiuwen Lan,Yanwei Zhang,Xiyang Zhang,Han Sun,Yong Zhang,Ying Zhang,Baofeng Yang

DOI: https://doi.org/10.1016/j.vph.2022.107126

IF: 5.738

2022-11-08

Vascular Pharmacology

Abstract:Diabetic mellitus (DM) complicated with myocardial infarction (MI) is a serious clinical issue that remained poorly comprehended. The aim of the present study was to investigate the role of NAD + in attenuating cardiac damage following MI in diabetic mice. The cardiac dysfunction in DM mice with MI was more severe compared with the non-diabetic mice and NAD + administration could significantly improve the cardiac function in both non-diabetic and diabetic mice after MI for both 7 days and 28 days. Moreover, application of NAD + could markedly reduce the cardiac injury area of DM complicated MI mice. Notably, the level of NAD + was robustly decreased in the cardiac tissue of MI mice, which was further reduced in the DM complicated mice and NAD + administration could significantly restore the NAD + level. Furthermore, NAD + was verified to facilitate the angiogenesis in the MI area of both diabetic mice and non-diabetic mice by microfil perfusion assay and immunofluorescence. Additionally, we demonstrated that NAD + promoted cardiac angiogenesis after myocardial infarction in diabetic mice by promoting the M2 polarization of macrophages. At the molecular level, NAD + promoted the secretion of VEGF in macrophages and therefore facilitating migration and tube formation of endothelial cells. Mechanistically, NAD + was found to promote the generation of pro-angionesis VEGF 165 and inhibit the generation of anti-angionesis VEGF 165b via regulating the alternative splicing factors of VEGF (SRSF1 and SRSF6) in macrophages. The effects of NAD + were readily reversible on deficiency of it. Collectively, our data showed that NAD + could attenuate myocardial injury via regulating the alternative splicing of VEGF and promoting angiogenesis in diabetic mice after myocardial infarction. NAD + administration may therefore be considered a potential new approach for the treatment of diabetic patients with myocardial infarction.

pharmacology & pharmacy